Radius Recycling, Inc. - RDUS STOCK NEWS

Radius Health (Nasdaq: RDUS) filed its definitive proxy statement for the 2022 Annual Meeting of Stockholders, scheduled for July 8, 2022. The company urges shareholders to vote for its independent director nominees—Catherine J. Friedman, Jean-Pierre Garnier, Ph.D., and Andrew C. von Eschenbach, M.D.—to support continued progress under a refreshed Board and management. Key achievements since 2020 include a 20% reduction in SG&A expenses, a 66% increase in net revenue per employee, and a strengthened capital structure aimed at long-term value creation.

Radius Health provided an update on its abaloparatide transdermal system (abalo-TDS) development program. Following regulatory feedback, the company determined that an additional clinical trial is needed to proceed, with a potential launch now pushed to the second half of 2025. Consequently, Radius will cease work on abalo-TDS, eliminating prospective costs exceeding $100 million over the next three years. The decision reflects a strategic capital management approach amid delays and additional funding requirements.

Radius Health, Inc. (Nasdaq: RDUS) announced the appointment of Jennifer A. Jarrett and Susan Vissers Lisa as new independent directors, enhancing the Board's expertise and gender diversity. Both directors bring significant experience from the life sciences sector, with Jarrett serving as COO of Arcus Biosciences and Lisa as former Senior VP of Investor Relations at CVS Health. In addition, the Board proposed corporate governance changes to allow easier charter amendments and implement proxy access for long-term shareholders. These changes aim to align interests with shareholders.

The EMERALD phase 3 clinical trial has successfully met its primary endpoints, demonstrating that elacestrant significantly improves progression-free survival (PFS) in patients with ER+/HER2- advanced breast cancer. The 12-month PFS rate for elacestrant was 22.3% compared to 9.4% for standard treatments. Notably, elacestrant reduced the risk of disease progression or death by 30% overall and 45% for patients with ESR1 mutations. This marks elacestrant as the first oral selective estrogen receptor degrader with significant benefits in a phase 3 trial, with continued research planned for combination therapies.

Radius Health reported Q1 2022 net revenue of $43 million, slightly down from $45 million in Q1 2021, aligning with its 1H 2022 target of $97 million. The company reiterated its full-year TYMLOS revenue guidance of $232 million. A 4% increase in average active patients was noted. However, a net loss of $18.3 million was recorded, compared to $15.7 million in Q1 2021. Noteworthy developments include a filed sNDA for TYMLOS in men and a new patent extending exclusivity to 2040.

Radius Health (Nasdaq: RDUS) is set to release its first quarter 2022 financial results on May 5, 2022. A conference call will be held at 8:30 a.m. ET to discuss the results and provide a business update. Interested parties can join via domestic dial-in number 1 (866) 323-7965 or internationally at 1 (346) 406-0961, using conference ID 5844208. The call will also be streamed live and archived for future access on Radius's website. This event underscores Radius's commitment to keeping investors informed on its financial performance.

Radius Health will host a webcast on April 5, 2022, from 10:00 AM to 12:00 PM ET to discuss RAD011, an investigational synthetic cannabidiol oral solution. The webinar aims to provide insights on the asset's overview, scientific data, regulatory status, and clinical progress since acquisition. Key topics include its therapeutic potential for neuro-endocrine and neurodevelopmental conditions, including Prader-Willi and Angelman syndromes. The event will feature presentations by various experts and a Q&A session for investors and analysts.

Radius Health, Inc. (Nasdaq: RDUS) has appointed Mark Conley as Chief Financial Officer and promoted Kim Clarke to General Counsel as of March 16, 2022. Conley, with over 30 years of experience in finance, previously held roles at Kaleido Biosciences and Thermo Fisher Scientific. Clarke, who joined Radius in 2021, has a background in regulatory affairs from her time at GlaxoSmithKline. Both will report to CEO Kelly Martin and are expected to enhance Radius's leadership as it progresses in addressing medical needs in bone health, orphan diseases, and oncology.

Radius Health, Inc. (NASDAQ: RDUS) has extended its research collaboration with Massachusetts General Hospital to develop novel oral SIK inhibitors for musculoskeletal diseases, building on successful nonclinical data. The collaboration aims to progress a candidate molecule for treating disorders like osteoporosis. Additionally, a new patent for TYMLOS® has been issued, extending its exclusivity until January 10, 2040. This strengthens Radius' intellectual property and supports future developments in therapies for osteoporosis and related conditions.